The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
Open accessThe DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.
Abstract
Emerging evidence suggests that FcγR-mediated cross-linking of tumor-bound mAbs may induce signaling in tumor cells that contributes to their therapeutic activity. In this study, we show that daratumumab (DARA), a therapeutic human CD38 mAb with a broad-spectrum killing activity, is able to induce programmed cell death (PCD) of CD38+ multiple myeloma tumor cell lines when cross-linked in vitro by secondary Abs or via an FcγR. By comparing DARA efficacy in a syngeneic in vivo tumor model using FcRγ-chain knockout or NOTAM mice carrying a signaling-inactive FcRγ-chain, we found that the inhibitory FcγRIIb as well as activating FcγRs induce DARA cross-linking–mediated PCD. In conclusion, our in vitro and in vivo data show that FcγR-mediated cross-linking of DARA induces PCD of CD38-expressing multiple myeloma tumor cells, which potentially contributes to the depth of response observed in DARA-treated patients and the drug’s multifaceted mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219 · cited 1×
“The homotypic aggregation–related caspase-independent and -dependent PCD was also shown for SAR650984, a chimeric CD38 Ab (40, 41), in the absence of secondary cross-linking.”
BackgroundRetractedKyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Zamzami, N., Marchetti, P., Castedo, M., Zanin, C., Vayssière, J. L., Petit, P. X., & Kroemer, G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.5.1661 · Cited by 1,166
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 1×
“Approval was based on two phase II studies of DARA monotherapy (16 mg/kg) in heavily treated patients (2, 3).”
Methodde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationMössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
FcR γ chain deletion results in pleiotrophic effector cell defects
Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90115-5 · Cited by 951
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · cited 1×
“Approval was based on two phase II studies of DARA monotherapy (16 mg/kg) in heavily treated patients (2, 3).”
MethodApoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 576
Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy
Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.817 · Cited by 543
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521 · cited 6×
“to be highly potent in phagocytosis induction (6), and there-”
BackgroundSelf-citationFlow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma
Lin, P. Y., Owens, R., Tricot, G. J. K., & Wilson, C. S. (2004) · American Journal of Clinical Pathology · doi:10.1309/74r4-tb90-buwh-27jx · Cited by 454
Usmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407
Deckert, J., Wetzel, M.-C., Bartle, L. M., Skaletskaya, A., Goldmacher, V. S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0695 · Cited by 333 · cited 1×
“The homotypic aggregation–related caspase-independent and -dependent PCD was also shown for SAR650984, a chimeric CD38 Ab (40, 41), in the absence of secondary cross-linking.”
BackgroundThe phosphatidylserine receptor: a crucial molecular switch?
Henson, P. M., Bratton, D. L., & Fadok, V. A. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35085094 · Cited by 321
Zheng, Y., Cai, Z., Wang, S., Zhang, X., Qian, J., Hong, S., Li, H., Wang, M., Yang, J., & Yi, Q. (2009) · Blood · doi:10.1182/blood-2009-05-220285 · Cited by 307
Alduaij, W., Ivanov, A., Honeychurch, J., Cheadle, E. J., Potluri, S., Lim, S. H., Shimada, K., Chan, C. H. T., Tutt, A., Beers, S. A., et al. (2011) · Blood · doi:10.1182/blood-2010-07-296913 · Cited by 294
Serial Killing of Tumor Cells by Human Natural Killer Cells – Enhancement by Therapeutic Antibodies
Bhat, R., & Watzl, C. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000326 · Cited by 286
Horenstein, A. L., Chillemi, A., Zaccarello, G., Bruzzone, S., Quarona, V., Zito, A., Serra, S., & Malavasi, F. (2013) · OncoImmunology · doi:10.4161/onci.26246 · Cited by 279
Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 248
Crosstalk between Human IgG Isotypes and Murine Effector Cells
Overdijk, M. B., Verploegen, S., Ortiz Buijsse, A., Vink, T., Leusen, J. H. W., Bleeker, W. K., & Parren, P. W. H. I. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200356 · Cited by 229
Self-citationLammerts van Bueren, J., Jakobs, D., Kaldenhoven, N., Roza, M., Hiddingh, S., Meesters, J., Voorhorst, M., Gresnigt, E., Wiegman, L., Ortiz Buijsse, A., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3474.3474 · Cited by 222
Self-citationChan, H. T. C., Hughes, D., French, R. R., Tutt, A. L., Walshe, C. A., Teeling, J. L., Glennie, M. J., & Cragg, M. S. (2003) · PubMed · Cited by 211
Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4
Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Marsters, S. A., Koeppen, H., Ashkenazi, A., & Kim, K. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4891 · Cited by 202
Bologna, L., Gotti, E., Manganini, M., Rambaldi, A., Intermesoli, T., Introna, M., & Golay, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000303 · Cited by 200
Ivanov, A., Beers, S. A., Walshe, C. A., Honeychurch, J., Alduaij, W., Cox, K. L., Potter, K. N., Murray, S., Chan, C. H. T., Klymenko, T., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37884 · Cited by 177
Honeychurch, J., Alduaij, W., Azizyan, M., Cheadle, E. J., Pelicano, H., Ivanov, A., Huang, P., Cragg, M. S., & Illidge, T. M. (2012) · Blood · doi:10.1182/blood-2011-12-395541 · Cited by 131
In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
de Haij, S., Jansen, J. H. M., Boross, P., Beurskens, F. J. M., Bakema, J. E., Bos, D. L., Martens, A. C., Verbeek, J. S., Parren, P. W. H. I., van de Winkel, J. G. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4109 · Cited by 130
Self-citationMateo, V., Brown, E. J., Biron, G., Rubio, M., Fischer, A., Deist, F. L., & Sarfati, M. (2002) · Blood · doi:10.1182/blood-2001-12-0217 · Cited by 129
Cerisano, V., Aalto, Y., Perdichizzi, S., Bernard, G., Manara, M. C., Benini, S., Cenacchi, G., PREDA, P., Lattanzi, G., Nagy, B., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207741 · Cited by 129
Beurskens, F. J., Lindorfer, M. A., Farooqui, M., Beum, P. V., Engelberts, P., Mackus, W. J. M., Parren, P. W. H. I., Wiestner, A., & Taylor, R. P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103693 · Cited by 119
Self-citationLi, F., & Ravetch, J. V. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319502110 · Cited by 115
Ghetie, M.-A., Podar, E. M., Ilgen, A., Gordon, B. E., Uhr, J. W., & Vitetta, E. S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7509 · Cited by 112
Xu, Y., Szalai, A. J., Zhou, T., Zinn, K. R., Chaudhuri, T. R., Li, X., Koopman, W. J., & Kimberly, R. P. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.562 · Cited by 108
Chaouchi, N., Vázquez, A., Galanaud, P., & Leprince, C. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.7.3096 · Cited by 96
Vaughan, A. T., Iriyama, C., Beers, S. A., Chan, H. T. C., Lim, S. H., Williams, E. L., Shah, V., Roghanian, A., Frendéus, B., Glennie, M. J., et al. (2013) · Blood · doi:10.1182/blood-2013-04-490821 · Cited by 81
A Humanized Mouse Identifies the Bone Marrow as a Niche with Low Therapeutic IgG Activity
Lux, A., Seeling, M., Baerenwaldt, A., Lehmann, B., Schwab, I., Repp, R., Meidenbauer, N., Mackensen, A., Hartmann, A., Heidkamp, G. F., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.041 · Cited by 53
Kuipers, J., Vaandrager, J., Weghuis, D. O., Pearson, P. L., Scheres, J. M. J. C., Lokhorst, H. M., Clevers, H. C., & Bast, B. J. E. G. (1999) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(98)00157-5 · Cited by 51
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs
White, A. L., Chan, H. T. C., French, R. R., Beers, S. A., Cragg, M. S., Johnson, P., & Glennie, M. J. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1398-6 · Cited by 49
Rozemuller, H., van der Spek, E., Bogers-Boer, L., Zwart, M. C., Verweij, V., Emmelot, M. E., Groen, R. W. J., Spaapen, R. M., Bloem, A. C., Lokhorst, H. M., et al. (2008) · Haematologica · doi:10.3324/haematol.12349 · Cited by 48
Self-citationOverdijk, M. B., Verploegen, S. A. B. W., van den Brakel, J. H. N., van Bueren, J. J. L., Vink, T., van de Winkel, J. G. J., Parren, P. W. H. I., & Bleeker, W. K. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003926 · Cited by 45
Self-citationA general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies
Li, F., & Ravetch, J. V. (2012) · Cell Cycle · doi:10.4161/cc.21842 · Cited by 36
van Vugt, M. J., van den Herik–Oudijk, I. E., & van de Winkel, J. G. J. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00666.x · Cited by 22
Lee, B., Kang, S. U., Hwang, H. S., Kim, Y., Sung, E.-S., Shin, Y. S., Lim, Y. C., & Kim, C. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.007 · Cited by 18
Mattes, M. J., Michel, R. B., Goldenberg, D. M., & Sharkey, R. M. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0567 · Cited by 12
Heterogeneous expression of CD32 and CD32-mediated growth suppression in human myeloma cells.
Zheng, X., Abroun, S., Otsuyama, K., Asaoku, H., & Kawano, M. M. (2006) · PubMed · Cited by 9
Nijhof, I. S., Lokhorst, H. M., van Kessel, B., Groen, R. W. J., Martens, A. C., Doshi, P. D., Klein, S. K., Mutis, T., Sasser, K., & van de Donk, N. W. C. J. (2014) · Blood · doi:10.1182/blood.v124.21.2096.2096 · Cited by 4
Self-citation
Cited by
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
Kastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala, V., Gibbs, S., Mollee, P., Venner, C. P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028631 · Cited by 702
Voorhees, P. M., Kaufman, J. L., Laubach, J., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L. J., Anderson, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020005288 · Cited by 693
Metadata
- Authors
- Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P.
- Affiliations
- Genmab (Netherlands) (NL)
- University Medical Center Utrecht (NL)
- Genmab , 3584 CM Utrecht,
- University of Southern Denmark (DK)
- Immunotherapy Laboratory, Laboratory for Translational Immunology, University Medical Center , 3584 CX Utrecht,
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-08-01
- Volume
- 197
- Issue
- 3
- Pages
- 807-813
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2443548094
- Cited by
- 297
- References
- 51
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 21 · 2023: 27 · 2022: 35 · 2021: 45 · 2020: 44 · 2019: 34 · 2018: 27 · 2017: 19 · 2016: 4
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- The Journal of Immunology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- daratumumab, anti-CD38 monoclonal antibody, programmed cell death, multiple myeloma, FcRγ chain, FcγRIIB, FcγRIII, antibody-dependent cellular cytotoxicity
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Disease Models, Animal, Humans, Mice, Inbred C57BL, Multiple Myeloma, Tumor Cells, Cultured, Apoptosis, Receptors, IgG, Mice, Knockout, Mice, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.